Lupin expects 25-30 product approvals in FY16
The company aims to focus majorly on two therapeutic areas of dermatology and respiratory.
Mumbai, April 20, 2015: The Indian pharma company Lupin plans to focus on two therapeutic areas of dermatology and respiratory and is expecting close to 25-30 product approvals in FY16, according to a report by Barclays Equity Research.
"Approvals in the US continue to be a work-in-progress although Lupin management believes that the number of approvals should improve sequentially going ahead. Management highlighted that the company is expecting 25-30 approvals in FY 2016 with the number for FY 2017 likely to be even higher than this," Barclays Equity Research said in its recent report.
The company has already received close to 10 final approvals in the past 12 months and is ahead of its domestic competition on this front.